AKAO 2018 Proxy Statement

25 EXECUTIVE OFFICERS The following is biographical information for our executive officers, including their ages as of March 31, 2018. Name Age Position(s) Blake Wise 47 Chief Executive Officer Kenneth J. Hillan, M.B., Ch.B. 57 President, R&D and President of Achaogen Gary Loeb 48 General Counsel, Corporate Secretary and Chief Compliance Officer Tobin C. Schilke 43 Chief Financial Officer Lee Swem, Ph.D. 42 Chief Scientific Officer Kenneth J. Hillan, M.B., Ch.B. Dr. Hillan has served as an executive officer and as a member of our board of directors since 2011. Please see Dr. Hillan’s biography set forth above in the section entitled “Proposal 1 Election of Directors.” Blake Wise . Mr. Wise has served as our Chief Executive Officer and as a member of our board of directors since January 2018. Please see Mr. Wise’s biography set forth above in the section entitled “Proposal 1 Election of Directors”. Gary Loeb . Mr. Loeb has served as our General Counsel and Corporate Secretary since November 2016 and our Chief Compliance Officer since December 2017. He previously served as General Counsel of Sano Intelligence Inc., a medical device company, from November 2015 to June 2016, and as Executive Vice President, Business Development and General Counsel of Counsyl, Inc., a health technology company, where he worked from August 2013 to November 2015. Mr. Loeb worked for Amyris Inc., an industrial bioscience company, from 2011 to July 2013, where he served as served as General Counsel, Senior Vice President and Chief Compliance Officer. Prior to that, he was with Genentech, from 2000 to 2011, where he served as Vice President, Intellectual Property. From January 2006 to May 2015, Mr. Loeb was also an adjunct professor at University of San Francisco Law School. Mr. Loeb is currently on the board of directors for Project Open Hand, a nonprofit organization, and is on the Board of The Columbia Law School Association from 2016 through Summer 2018. Mr. Loeb holds a B.S. in Biology and a B.A. in English from Stanford University and a J.D. from Columbia Law School. Tobin C. Schilke . Mr. Schilke has served as our Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer since July 2016. From 2002 to June 2016, Mr. Schilke served in roles of increasing responsibility at the Roche Group (including Genentech), a pharmaceutical company, including serving as Finance Director and Company Director of Roche Products Limited in the United Kingdom from August 2014 to June 2016 and serving as Director of Genentech’s Commercial Finance BioOncology Business Unit from September 2012 to August 2014. Mr. Schilke holds a B.S. from Lafayette College, a M.S. from the University of California, Berkeley and an M.B.A. from Cornell University’s Johnson Graduate School of Management. Lee Swem, Ph.D . Dr. Swem has served as our Chief Scientific Officer since February 2017 and, prior to that, served as our Vice President, Head of Research since October 2015. From August 2014 to September 2015, Dr. Swem was Director of our Therapeutic Antibody Program, where he developed a state-of-the-art antibody discovery platform to rapidly identify rare functional antibodies to treat serious human infectious diseases. Before joining Achaogen, Dr. Swem was with Genentech, where he served as a Consultant from August 2014 to August 2015 and a Scientist in Genentech’s Department of Infectious Disease from 2010 to August 2014. Dr. Swem completed his postdoctoral work at Princeton University. He received a B.S. in Biology and a Ph.D. in Microbiology from Indiana University.